Enter Note Done
Go to previous page in this tab
Session
  • Presentation | General Poster Session - Monday General Poster Session
  • General Poster Session
  • Share Icon
    Map Icon
    Bookmark Icon
  • 2648-P - A Phase 1, Randomized, Double-Blind, Single-Ascending Dose Study of KAI-9531, a Novel Dual GLP-1/GIP Receptor Agonist in Development for People Living with Overweight/Obesity [Board No. 2648]
    • Schedule
    Notes
  • 2648-P
    Set Timezone
    •  
    Route Me

L. Klickstein: Employee; Ended; Eli Lilly and Company. A.M. Clark: Employee; Current; Kailera Therapeutics. C.S. Djedjos: Employee; Current; Kailera Therapeutics. A. Fernald: None. H. Zhang: None. S. Wasserman: Employee; Current; Kailera Therapeutics. A.C. Moses: Consultant; Current; Virta Health Corp., Vertex Pharmaceuticals Incorporated, Novo Nordisk A/S. Advisory Panel; Current; TixiMed. Stock/Shareholder; Current; Minutia. Advisory Panel; Current; Kailera, Metabolics Pharma. Consultant; Current; 3D Communication.
Type
Main Session